- Conditions
- HIV Infection
- Interventions
- DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 641 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 183
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Interventions
- Atazanavir, Cobicistat, Atazanavir/Cobicistat FDC
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- HIV Infections
- Interventions
- GSK3640254, DTG, GSK3640254/DTG
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Chronic HCV Infection
- Interventions
- LDV/SOF, SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 13
- States / cities
- Sacramento, California • San Diego, California • San Francisco, California + 9 more
- Conditions
- Hepatitis C, HIV-1-infection, Liver Diseases
- Interventions
- Sofosbuvir/Velpatasvir (SOF/VEL), Minimal Monitoring (MINMON) Strategy
- Drug · Other
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
- Conditions
- Chronic HCV Infection
- Interventions
- LDV/SOF, RBV, GS-9669
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- HIV-1 Infection
- Interventions
- B/F/TAF, NRTIs, Third Agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 40
- States / cities
- Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
- Conditions
- HIV Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
- Conditions
- Healthy
- Interventions
- Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC, 1 tablet Empagliflozin/2 tablets Metformin XR, 1 tablet Empagliflozin/3 tablets Metformin XR
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Hypertension
- Interventions
- Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 39
- States / cities
- Foley, Alabama • Carmichael, California • Los Angeles, California + 33 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-445/TEZ/IVA, TEZ/IVA, IVA, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 24 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- LDV/SOF, VDV, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hypertension (HTN)
- Interventions
- Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- Healthy
- Interventions
- lesinurad/allopurinol 200/300 FDC tablet, lesinurad 200 mg, allopurinol 300 mg
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Chronic Hepatitis B
- Interventions
- TDF, ADV, TDF placebo, ADV placebo, FTC/TDF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 20
- States / cities
- Orange, California • Pasadena, California • San Diego, California + 14 more
- Conditions
- Cystic Fibrosis
- Interventions
- VNZ/TEZ/D-IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Dapagliflozin, Metformin XR, Glucophage
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
- Interventions
- Lumacaftor Plus Ivacaftor Combination, Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
- Conditions
- Healthy
- Interventions
- FDC of Macitentan and Tadalafil, Macitentan, Tadalafil
- Combination Product · Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- Dolutegravir, Lamivudine, Dolutegravir + Lamivudine FDC Formulation 1, Dolutegravir + Lamivudine FDC Formulation 2
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy
- Interventions
- Relugolix/E2/NETA FDC, Relugolix, Erythromycin
- Drug
- Lead sponsor
- Myovant Sciences GmbH
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- HIV-1 Infection
- Interventions
- FTC/RPV/TAF, EFV/FTC/TDF Placebo, EFV/FTC/TDF, FTC/RPV/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 79
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Long Beach, California + 57 more
- Conditions
- Healthy Volunteers
- Interventions
- CANA/MET XR FDC
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska